PDS Biotechnology Corp
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
PDSB$1.03-4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
| Common Stock | |||||
|---|---|---|---|---|---|
| Shares Issued | Amount | Additional Paid-in Capital | Accumulated Deficit | Total Equity | |
| January 1, 2023 | 30,170,317 | $9,956 | $145,550,491 | $(101,558,417) | $44,002,030 |
| Stock-based compensation expense | – | – | 2,080,319 | – | 2,080,319 |
| Issuances of common stock from the Sales Agreement, net | 553,293 | 183 | 4,588,339 | – | 4,588,522 |
| Net loss | – | – | – | (9,659,918) | (9,659,918) |
| Balance - March 31, 2023 | 30,723,610 | $10,139 | $152,219,149 | $(111,218,335) | $41,010,953 |
| Stock-based compensation expense | – | – | 2,105,538 | – | 2,105,538 |
| Issuances of common stock, from exercise of stock options | 1,409 | 1 | 8,848 | – | 8,849 |
| Issuance of common stock for consulting agreement | 100,000 | 33 | 609,967 | – | 610,000 |
| Issuances of common stock from the Sales Agreement, net | 43,169 | 14 | 243,729 | – | 243,743 |
| Net loss | – | – | – | (11,534,895) | (11,534,895) |
| Balance - June 30, 2023 | 30,868,188 | $10,187 | $155,187,231 | $(122,753,230) | $32,444,188 |
| Stock-based compensation expense | – | – | 2,073,607 | – | 2,073,607 |
| Issuances of common stock from the Sales Agreement, net | 139,575 | 46 | 815,156 | – | 815,202 |
| Net loss | – | – | – | (10,849,169) | (10,849,169) |
| Balance - September 30, 2023 | 31,007,763 | $10,233 | $158,075,994 | $(133,602,399) | $24,483,828 |
| Common Stock | |||||
|---|---|---|---|---|---|
| Shares Issued | Amount | Additional Paid-in Capital | Accumulated Deficit | Total Equity | |
| January 1, 2024 | 33,094,521 | $10,921 | $170,620,641 | $(144,500,615) | $26,130,947 |
| Stock-based compensation expense | – | – | 1,630,011 | – | 1,630,011 |
| Issuances of common stock from the Sales Agreement, net | 3,428,681 | 1,131 | 19,493,342 | – | 19,494,473 |
| Issuances of common stock, from exercise of stock options | 156,073 | 52 | 531,039 | – | 531,091 |
| Net loss | – | – | – | (10,603,477) | (10,603,477) |
| Balance - March 31, 2024 | 36,679,275 | $12,104 | $192,275,033 | $(155,104,092) | $37,183,045 |
| Stock-based compensation expense | – | – | 1,795,722 | – | 1,795,722 |
| Issuance of common stock for consulting agreement | 100,000 | 33 | 266,967 | – | 267,000 |
| Net loss | – | – | – | (8,327,897) | (8,327,897) |
| Balance - June 30, 2024 | 36,779,275 | $12,137 | $194,337,722 | $(163,431,989) | $30,917,870 |
| Stock-based compensation expense | – | – | 1,778,272 | – | 1,778,272 |
| Amortization of issuance costs related to the Sales Agreement | – | – | (67,179) | – | (67,179) |
| Issuances of common stock, from exercise of stock options | 40,535 | 13 | 98,487 | – | 98,500 |
| Net loss | – | – | – | (10,726,658) | (10,726,658) |
| Balance - September 30, 2024 | 36,819,810 | $12,150 | $196,147,302 | $(174,158,647) | $22,000,805 |
Index
Condensed Consolidated
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.